Herve Curé

Herve Curé

UNVERIFIED PROFILE

Are you Herve Curé?   Register this Author

Register author
Herve Curé

Herve Curé

Publications by authors named "Herve Curé"

Are you Herve Curé?   Register this Author

46Publications

1294Reads

28Profile Views

Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work.

Breast Cancer Res Treat 2018 Apr 14;168(2):433-441. Epub 2017 Dec 14.

Department of Medical Oncology, Lyon Sud University Hospital, Hospices Civils de Lyon and Lyon University, Pierre-Bénite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4607-8DOI Listing
April 2018

The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.

Oncology 2016 16;90(2):69-78. Epub 2016 Jan 16.

Oncology Department, Centre Jean Perrin, and University Clermont 1, UFR Mx00E9;decine, and Centre d'Investigation Clinique, Clermont-Ferrand, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000441148DOI Listing
June 2016

Management of anemia and iron deficiency in a cancer center in France.

Support Care Cancer 2016 Mar 8;24(3):1091-6. Epub 2015 Aug 8.

Jean Godinot Unicancer Institute, 1 avenue du général Köenig, CS80014, 51726, Reims, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-015-2877-4DOI Listing
March 2016

Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French survey.

Anticancer Res 2014 Sep;34(9):5007-15

Department of Medical Oncology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.

View Article

Download full-text PDF

Source
September 2014

[External review of integrative oncology or complementary therapies use. Based on US academic cancer center].

Bull Cancer 2014 Jun;101(6):531-2

Institut Jean-Godinot, Centre de lutte contre le cancer de Champagne-Ardenne, 1, rue du Général-Kœnig, 51100 Reims, France, Université de Reims, Champagne-Ardenne, 51, rue Cognac-Jay, 51095 Reims, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2014.1980DOI Listing
June 2014

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

J Clin Oncol 2014 Feb 23;32(4):320-6. Epub 2013 Dec 23.

Ignace B. Vergote and Evelyn Despierre, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven; Corneel Coens, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Antonio Jimeno, University of Colorado School of Medicine, Aurora, CO; Florence Joly, Centre François Baclesse Caen, Caen; Anne Lesoin, Centre Oscar Lambret, Lille; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Laure Favier, Centre Georges François Leclerc, Dijon; Hervé Curé, Unicancer Institut Jean Godinot, Reims; Eric Pujade-Lauraine, Hôpital Hôtel-Dieu, Paris, France; Dionyssios Katsaros, University of Turin; Annamaria Ferrero, Ospedale Mauriziano Umberto I, Turin; Nicoletta Colombo, University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, Italy; Christian Marth, Medical University of Innsbruck, Innsbruck; Alexander Reinthaller, Medical University of Vienna, Vienna, Austria; Marcia Hall, Mount Vernon Cancer Centre, Middlesex; John Green, University of Liverpool, Liverpool; Nick Simon Reed, Gartnavel General Hospitals, Glasgow, United Kingdom; Christopher B. Steer, Border Medical Oncology, Wodonga; Martin Buck, Government of Western Australia, Department of Health, Perth, Australia; and Antonio Casado, Universitario San Carlos, Madrid, Spain.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2013/12/23/JCO.2013.50
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.50.5669
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.50.5669DOI Listing
February 2014

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.

Breast 2013 Dec 20;22(6):1060-5. Epub 2013 Sep 20.

Breast Cancer Translational Research Laboratory, J.C. Heuson, Université Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium; Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.08.014DOI Listing
December 2013

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.

Sci Rep 2013 Dec 9;3:3456. Epub 2013 Dec 9.

1] Institut National de la Santé et de la Recherche Médicale (INSERM) UMR-S 976; Université Paris Diderot, Sorbonne Paris Cité, Laboratoire Immunologie Dermatologie & Oncologie, F-75475, Paris, France [2].

View Article

Download full-text PDF

Source
http://www.nature.com/articles/srep03456
Publisher Site
http://dx.doi.org/10.1038/srep03456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856404PMC
December 2013

Muc1/Cd227 immunohistochemistry in routine practice is a useful biomarker in breast cancers.

J Immunoassay Immunochem 2013 ;34(3):232-45

Institut Jean Godinot, Biopathology, Reims, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15321819.2012.699491DOI Listing
November 2013

Fine-needle aspiration cytology can play a role in neoadjuvant chemotherapy in operable breast cancer.

ISRN Oncol 2013 10;2013:935796. Epub 2013 Jul 10.

Departments of Biopathology and Medical Oncology, Institut Jean-Godinot-Unicancer, 51726 Reims Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/935796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725715PMC
August 2013

Positron Emission Tomography in oncology: present and future of PET and PET/CT.

Crit Rev Oncol Hematol 2009 Dec 16;72(3):239-54. Epub 2008 Dec 16.

Service de Médecine Nucléaire, Institut Jean Godinot, Reims, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428080025
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2008.10.006DOI Listing
December 2009

[Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer].

Bull Cancer 2006 Nov;93(11):1121-9

Département d'oncologie médicale et Unité de recherche clinique, Centre Jean-Perrin, Clermont-Ferrand.

View Article

Download full-text PDF

Source
November 2006

Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.

Clin Breast Cancer 2006 Oct;7(4):336-8

Centre Jean Perrin, Bureau de Recherche Clinique, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2006.n.047DOI Listing
October 2006

[Place of anatomopathology in evaluation of response to neoadjuvant chemotherapy. Prognostic and predictive markers: example of breast cancer].

Bull Cancer 2006 Jul;93(7):663-8

Unité de recherche clinique, Centre Jean-Perrin, 58, rue Montalembert, BP392, 63011 Clermont-Ferrand Cedex 1.

View Article

Download full-text PDF

Source
July 2006

Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.

J Urol 2006 Apr;175(4):1347-52

Centre Jean Perrin, Clermont-Ferrand, France; UMR484 INSERM, Clermont-Ferrand, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0022-5347(05)00640-3DOI Listing
April 2006

Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase II trial.

Anticancer Drugs 2005 Oct;16(9):1003-7

Unité d'Oncologie Appliquée, Centre Jean Perrin, Centre Hospitalier et Universitaire, Clermont-Ferrand, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.cad.0000176506.71304.caDOI Listing
October 2005

In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment.

Anticancer Drugs 2005 Apr;16(4):417-22

UMR484 INSERM, Centre Jean Perrin, Université d'Auvergne, Clermont-Ferrand, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001813-200504000-00008DOI Listing
April 2005

[Management of a patient with cancer during all stages of the disease. Symptomatic treatment. Modalities of surveillance. Psychological, ethical and social problems].

Rev Prat 2004 Nov;54(17):1949-55

Centre Jean-Perrin, Centre national de lutte contre le cancer, Clermont Ferrand.

View Article

Download full-text PDF

Source
November 2004

Assessment of circadian rhythms by actimetry in healthy subjects and patients with advanced colorectal cancer.

Oncol Rep 2003 May-Jun;10(3):733-7

Centre Jean Perrin, INSERM U484, Bureau de Recherche Clinique, 58 rue Montalembert, 63011 Clermont-Ferrand, France.

View Article

Download full-text PDF

Source
December 2003